Evaluation of Electronic Prescribing in Hospital Ambulatory Care Clinics
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00252395|
Recruitment Status : Completed
First Posted : November 11, 2005
Last Update Posted : November 11, 2005
All reliably evaluated POE systems to date have been desktop computer based, but now there is widespread use and acceptance among physicians of PDA devices for a variety of purposes. Clinicians report that drug information on a PDA improved their access to information and efficiency while reducing their self perceived error rates6. The use of these devices for information retrieval in clinical settings is expected to grow as wireless communication becomes more ubiquitous and as more applications become available6,7. During the past decade there has been a growing awareness of several issues aimed at promoting safer health care for our patients – point of care information technology is one of the keys.
To this end we have worked with a Canadian company, Drugmagnet, to develop and implement PDA-based electronic prescribing system within a major Canadian academic health centre. This is a cluster randomised trial, in which access to and use of the e-prescribing system is switched on and off for randomly chosen weeks, thus time serves as the randomized element.
|Condition or disease||Intervention/treatment||Phase|
|Electronic Prescribing||Device: PDA-based Electronic Prescribing Software||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||40 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Effects of Electronic Prescribing on Safety and Quality in Hospital-Based Ambulatory Are: a Randomised Controlled Trial|
|Study Start Date :||August 2005|
|Study Completion Date :||August 2006|
- Total prescribing error, as measured by the number of call backs received from pharmacists.
- a) Interactions
- b) Dosing and route of administration errors
- c) Pack errors
- d) Legibility errors
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00252395
|Sunnybrook & Women's College Health Science Centre|
|Toronto, Ontario, Canada, M4N 3M5|
|Study Director:||Merrick F Zwarenstein, MBBCH||Institute for Clinical Evaluative Science|
|Principal Investigator:||William J Sibbald, MD, MPH||Sunnybrook & Women's College Health Sciences Centre|